Chip Stock Investor发布 2026-09-04
《Is PRCT a Value Trap After Its 80% Crash? We Ran the Numbers》
$PRCT看跌
PRCT是一个价值陷阱；除非发生结构性变化，否则应避免持有，因为其多次未达指引且利润率持续恶化。
Procept BioRobotics采用刀片与剃须刀业务模式，毛利率65%，医疗保险覆盖全美50个州，其手术在治疗前列腺增生的切除性疗法中基本仅次于TURP。
Procept BioRobotics, razor and blade business model, 65% gross margins, Medicare coverage in all 50 states, and a procedure that's basically second only to TURP among resective treatments for an enlarged prostate.
该股自2025年高点已下跌约80%，这一集讲述的是一款显然有效的产品，但它所依附的业务从未产生正现金流，并且在过去一年中多次下调指引。
The stock is down roughly about 80% from its highs in 2025, and this is an episode about a product that clearly works, attached to a business that has never generated positive cash flow, and that has revised guidance downward a number of times over the last year.